L9S Stock Overview
A pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Gyre Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$9.60 |
| 52 Week High | US$24.20 |
| 52 Week Low | US$9.10 |
| Beta | 0 |
| 1 Month Change | -27.27% |
| 3 Month Change | -49.21% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -55.56% |
Recent News & Updates
Recent updates
Shareholder Returns
| L9S | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -17.2% | 0.7% | -0.8% |
| 1Y | n/a | -23.9% | 3.2% |
Return vs Industry: Insufficient data to determine how L9S performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how L9S performed against the German Market.
Price Volatility
| L9S volatility | |
|---|---|
| L9S Average Weekly Movement | 14.6% |
| Biotechs Industry Average Movement | 5.2% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.6% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: L9S's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine L9S's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 593 | Han Ying | www.gyretx.com |
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. It offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under phase 3 studies for dermatomyositis and systemic sclerosis-associated interstitial lung disease, pneumoconiosis, and diabetic kidney disease. The company is also involved the development of F351 (Hydronidone), a structural derivative of ETUARY (Pirfenidone), under Phase 3 studies for the treatment of chronic hepatitis B liver fibrosis; and under Phase 1 studies for liver fibrosis associated with nonalcoholic associated steatohepatitis.
Gyre Therapeutics, Inc. Fundamentals Summary
| L9S fundamental statistics | |
|---|---|
| Market cap | €895.43m |
| Earnings (TTM) | -€80.79m |
| Revenue (TTM) | €106.64m |
8.4x
P/S Ratio-11.1x
P/E RatioIs L9S overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| L9S income statement (TTM) | |
|---|---|
| Revenue | US$115.69m |
| Cost of Revenue | US$4.49m |
| Gross Profit | US$111.20m |
| Other Expenses | US$198.85m |
| Earnings | -US$87.64m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.02 |
| Gross Margin | 96.12% |
| Net Profit Margin | -75.76% |
| Debt/Equity Ratio | 0% |
How did L9S perform over the long term?
See historical performance and comparison